Retinal Vein OcclusionNCT06757595
Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion
An observational study of Retinal Vein Occlusion, run by Zhongnan Hospital at 1 site in China.
Trial summary
To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Retinal Vein Occlusion
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2018to 25 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with RVO diagnosed by ophthalmic examination in the Second Clinical Hospital of Wuhan University from January 2018 to December 2024 were enrolled
Who may be able to join
- meeting the diagnostic criteria for RVO (including BRVO and CRVO)
Who cannot join
- patients with other ocular diseases other than RVO, such as iridocyclitis, age-related macular degeneration, central serous chorioretinopathy and optic neuropathy;
- patients with systemic inflammatory diseases and other systemic diseases other than diabetes, hypertension, coronary heart disease and cerebral infarction that may affect blood indexes;
- patients with incomplete clinical data and information.
Trial locations and contacts
1 site in 1 country.
About this study
To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.
Read the detailed description
To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.
Patients discharged from our hospital from January 2018 to December 2024 with the diagnosis of retinal vein occlusion were retrospectively investigated. The medical history of each patient was reviewed, and the basic information, past medical history, eye examinations and their results, treatment plans, and prognosis information of the patients were recorded in detail.
- Conditions
- Retinal Vein Occlusion
- Keywords
- Retinal Vein Occlusion, clinical feature, therapy
- Medical subject headings
- Retinal Vein Occlusion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| rvo patients | Not described | |
| Initial onset and meeting the diagnostic criteria for RVO (including BRVO and CRVO) | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Various underlying diseases, eye conditions, lifestyle, blood test results, imaging manifestations and treatment response
Age, gender, blood routine (platelet count, neutrophil count, monocyte count, and lymphocyte count), four coagulation tests (prothrombin time determination, activated partial thromboplastin time determination), blood lipid (total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein data), hypertension, diabetes, coronary heart disease, and cerebral infarction were collected in detail Death history, laser, anti-VEGF injection, hormone and other treatment methods and times, and the visual acuity at the last follow-up. The general conditions of the patients were statistically analyzed, such as the proportion of previous history of hypertension and diabetes, and the mean value of blood lipids, blood clotting images and other blood test results of the patients were calculated, and the correlation between them and the prognosis of vision was analyzed.
Measured: From January 2024 to January 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jan 2025
- Study start1 Jan 2018
- Primary completion25 Dec 2024
- Study completion25 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retinal Vein OcclusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zhongnan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06757595
- Sponsor's protocol ID
- 20241223
- Status last verified
- Nov 2024
- First submitted
- 25 Dec 2024
- Last updated
- 3 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion
- ClinicalTrials.gov ID
- NCT06757595
- Acronym / sponsor ID
- 20241223
- Conditions
- Retinal Vein Occlusion
- Keywords
- Retinal Vein Occlusion, clinical feature, therapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- Zhongnan HospitalUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 25 Dec 2024 (actual)
- Study completion
- 25 Dec 2024 (actual)
- First posted
- 3 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.
Detailed description
To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.
Patients discharged from our hospital from January 2018 to December 2024 with the diagnosis of retinal vein occlusion were retrospectively investigated. The medical history of each patient was reviewed, and the basic information, past medical history, eye examinations and their results, treatment plans, and prognosis information of the patients were recorded in detail.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| rvo patients | – | – |
| Initial onset and meeting the diagnostic criteria for RVO (including BRVO and CRVO) | – | – |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with RVO diagnosed by ophthalmic examination in the Second Clinical Hospital of Wuhan University from January 2018 to December 2024 were enrolled
Key inclusion criteria (1 listed)
- meeting the diagnostic criteria for RVO (including BRVO and CRVO)
Key exclusion criteria (3 listed)
- patients with other ocular diseases other than RVO, such as iridocyclitis, age-related macular degeneration, central serous chorioretinopathy and optic neuropathy;
- patients with systemic inflammatory diseases and other systemic diseases other than diabetes, hypertension, coronary heart disease and cerebral infarction that may affect blood indexes;
- patients with incomplete clinical data and information.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Various underlying diseases, eye conditions, lifestyle, blood test results, imaging manifestations and treatment response
Time frame: From January 2024 to January 2025
Age, gender, blood routine (platelet count, neutrophil count, monocyte count, and lymphocyte count), four coagulation tests (prothrombin time determination, activated partial thromboplastin time determination), blood lipid (total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein data), hypertension, diabetes, coronary heart disease, and cerebral infarction were collected in detail Death history, laser, anti-VEGF injection, hormone and other treatment methods and times, and the visual acuity at the last follow-up. The general conditions of the patients were statistically analyzed, such as the proportion of previous history of hypertension and diabetes, and the mean value of blood lipids, blood clotting images and other blood test results of the patients were calculated, and the correlation between them and the prognosis of vision was analyzed.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jan 2025.
Related trials for Retinal Vein Occlusion
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Not yet recruitingObservational study
A Case-Control Study Revealing Intraocular Microenvironment Characteristics in Patients With Ocular Diseases Based on Multi-Omics Analysis
Age- Related Macular Degeneration, Diabetic Retinopathy
RecruitingObservational study
National Eye Institute Biorepository for Retinal Diseases
Age-Related Macular Degeneration, Diabetic Retinopathy
Not yet recruitingPhase 4
Iopidine to Decrease Intraocular Pressure Rise After Injections
Macular Degeneration, Diabetic Retinopathy
Recruiting
Robotic RVO Trial: Robot-assisted Retinal Vein Cannulation in Patients With Retinal Vein Occlusions
Retinal Vein Occlusion (RVO)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Retinal Vein Occlusion, run by Zhongnan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Various underlying diseases, eye conditions, lifestyle, blood test results, imaging manifestations and treatment response (time frame: From January 2024 to January 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2025.